Brought to you by 
Shandong Luoxin gains exclusive rights to Yuhan's preclinical cancer project
16 Jul 2019
Executive Summary
Shandong Luoxin Pharmaceutical Group Co. Ltd. (also referred to as Shandong Elohim Pharmaceutical) licensed exclusive rights to develop, manufacture, and sell Yuhan Corp.'s preclinical non-small cell lung cancer candidate YH25448 in China, Hong Kong, and Macau.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Shandong Luoxin gains exclusive rights to Yuhan's preclinical cancer project
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice